We’re pleased to announce that the first patient has been enrolled in the MAINTAIN POP clinical trial, led by the REMIND group.

This study will assess the safety and efficacy of EXL01, our live biotherapeutic based on Faecalibacterium prausnitzii – a beneficial gut bacterium known to support long-term remission in Crohn’s.

EXL01 is designed to activate NOD2, a key immune receptor linked to Crohn’s disease, to help the body maintain an anti-inflammatory immune response after surgery.

This trial brings together top IBD centers across France and marks a key milestone in our mission to offer a safer, microbiome-based treatment for people living with Crohn’s.